Hyperdynamic circulation of cirrhotic rats: Role of substance P and its relationship to nitric oxide

Scandinavian Journal of Gastroenterology

Volumn 32, Issue 8, 1997, Pages 841-846

  Chu, C J ^a   Lee, F Y ^a,b   Wang, S S ^a   Chang, F Y ^a   Tsai, Y T ^a   Lin, H C ^a   Hou, M C ^a   Wu, S L ^a   Tai, C C ^a   Lee, S D ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Cirrhosis; Hyperdynamic circulation; Nitric oxide; Substance P

Indexed keywords

NITRIC OXIDE; SUBSTANCE P;

ADOLESCENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; HEART INDEX; LIVER CIRRHOSIS; LIVER DYSFUNCTION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; RAT; SYSTEMIC VASCULAR RESISTANCE;

EID: 0030745374     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365529708996544     Document Type: Article

References (49)

1. Vorobioff J, Bredfeldt JE, Groszmann RJ. Hyperdynamic circulation in portal hypertensive rat model: a primary factor for maintenance of chronic portal hypertension. Am J Physiol 1983;244:G52-7.
2. Groszmann RJ. Hyperdynamic circulation of liver disease 40 years later: pathophysiology and clinical consequences. Hepatology 1994;20:1359-63.
3. Pizcueta P, Piqué JM, Fernández M, Bosch J, Rodés J, Whittle BJR, et al. Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition. Gastroenterology 1992;103: 1909-15.
4. Sieber CC, Groszmann RJ. In vitro hyporeactivity to methoxamine in portal hypertensive rats: reversal by nitric oxide blockade. Am J Physiol 1992;262:G996-1001.
5. Lee FY, Albillos A, Colombato LA, Groszmann RJ. The role of nitric oxide in the vascular hyporesponsiveness to methoxamine in portal hypertensive rats. Hepatology 1992;16:1043-8.
6. ∞-nitro-L-arginine administration corrects peripheral vasodilatation and systemic capillary hypotension and ameliorates plasma volume expansion and sodium retention in portal hypertensive rats. Hepatology 1993;17:84-90.
7. Pizcueta MP, Piqué JM, Bosch J, Whittle BJR, Moncada S. Effects of inhibiting nitric oxide biosynthesis on the systemic and splanchnic circulation of rats with portal hypertension. Br J Pharmacol 1992;105:184-90.
8. Withrington PG. The actions of two sensory neuropeptides. substance P and calcitonin gene-related peptide, on the canine hepatic arterial and portal vascular beds. Br J Pharmacol 1992; 107:296-302.
9. Melchiorri P, Tonelli F, Negri L. Comparative circulatory effects of substance P, eledoisin and physalamin in the dog. In: Von Euler US, Pernow B, editors. Substance P. New York: Raven; 1977. p. 311-9.
10. Iverson LL. Substance P. Br Med Bull 1982;38:277-82.
11. Kabemura T, Misawa T, Chijiiwa Y, Nasu T, Nawata H. Substance P, vasoactive intestinal polypeptide, and gastrin catabolism in canine liver and kidney. Dig Dis Sci 1992;37:1661-5.
12. Ueno T, Inuzuka S, Torimura T, Sakata R, Sakamoto M, Gondo K. et al. Distribution of substance P and vasoactive intestinal peptide in the human liver: light and electron immunoperoxidase methods of observation. Am J Gastroenterol 1991;86:1633-7.
13. Saito R, Nonaka S. Konishi H, Takano Y, Shimohigashi Y, Matsumoto H, et al. Pharmacological properties of the tachykinin receptor subtype in the endothelial vasodilatation. Ann NY Acad Sci 1991;632:457-9.
14. Hörtnagl H, Singer EA, Lenz K, Kleinberger G, Lochs H. Substance P is markedly increased in plasma levels of patients with hepatic coma. Lancet 1984;1:480-3.
15. Nakamura Y, Parent R, Lavallée M. Disparate effects of substance P on systemic and coronary beds in conscious dogs. Circulation 1991;84:300-12.
16. Lee FY, Wang SS, Yang MCM, Tsai YT, Wu SL, Lu RH, et al. Role of endotoxemia in hyperdynamic circulation in rats with extrahepatic or intrahepatic portal hypertension. J Gastroenterol Hepatol 1996;11:152-8.
17. Chiang JH, Cheng HC, Yang MCM, Lo JG, Chi CW, Lui WY, et al. Lung deposit of lipiodol in normal and cirrhotic rats. Acta Radiol 1991;32:474-8.
18. Albillos A, Colombato LA, Groszmann RJ. Vasodilatation and sodium retention in prehepatic portal hypertension. Gastroenterology 1992;102:931-5.
19. Stuehr DJ, Marietta MA. Mammalian nitrate biosynthesis: mouse macrophages produce nitrite and nitrate in response to Escherichia coli lipopolysaccharide. Proc Natl Acad Sci USA 1985;82:7738-42.
20. Marietta MA, Poksyn SY, Iyengar R, Leaf CD, Wishnok JS. Macrophage oxidation of L-arginine to nitrite and nitrate: nitric oxide is an intermediate. Biochemistry 1988;27:8706-11.
21. Langrehr JM, Murase N, Markus PM, Cai X, Neuhaus P, Schraut W, et al. Nitric oxide production in host-versus-graft and graft-versus-host reactions in the rat. J Clin Invest 1992;90: 679-83.
22. Guarner C, Soriano G, Tomas A, Bulbena O, Novella MT, Balanzo J, et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology 1993;18:1139-43.
23. Hunt NCA, Goldin RD. Nitric oxide production by monocytes in alcoholic liver disease. J Hepatol 1992;14:146-50.
24. Henriksen JH, Schaffalitzky de Muckadell OB, Bülow JB. Does liver-intestine significantly degrade circulating endogenous substance P in man? Scand J Gastroenterol 1986;21:300-4.
25. Fernández-Rodriguez CM, Prieto J, Quiroga J, Zozoya JM, Andrade A, Núñez M, et al. Plasma levels of substance P in liver cirrhosis: relationship to activation of vasopressor systems and urinary sodium excretion. Hepatology 1995;21:35-40.
26. Mantyh PW, Pinnock RD, Downes CP, Goedert M, Hunt SP. Correlation between inositol phospholipid hydrolysis and substance P receptors in rat CNS. Nature 1984;309:795-7.
27. Hall JM, Brain SD. Inhibition by SR 140333 of NK, tachykinin receptor-evoked, nitric oxide-dependent vasodilatation in the hamster cheek pouch microvasculature in vitro. Br J Pharmacol 1994;113:522-6.
28. Petersson J, Zygmunt PM, Brandt L, Högestätt ED. Substance P-induced relaxation and hyperpolarization in human cerebral arteries. Br J Pharmacol 1995;115:889-94.
29. Zhang G, Yamamoto Y, Miwa K, Suzuki H. Vasodilatation induced by substance P in guinea pig carotid arteries. Am J Physiol 1994;266:H1132-7.
30. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilatation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;8:1151-7.
31. Dudley FJ. Pathophysiology of ascites formation. Gastroenterol Clin North Am 1992;21:215-35.
32. Granger DN, Taylor AE. Permeability of intestinal capillaries to endogenous macromolecules. Am J Physiol 1980;238:H457-64.
33. Henriksen JH, Parving H-H, Christiansen L, Winkler K, Lassen NA. Increased transvascular escape rate of albumin during experimental portal and hepatic venous hypertension in the pig. Relation to findings in patients with cirrhosis of the liver. Scand J Clin Invest 1981;41:289-99.
34. Witte CL, Chung YC, Witte MH, Sterle OF, Cole WR. Observations on the origin of ascites from experimental extrahepatic portal congestion. Ann Surg 1969;170:1002-15.
35. Witte CL, Myers JF, Witte MH, Katz MA. Transcapillary water and protein flux in the canine intestine with acute and chronic extrahepatic portal hypertension. Circ Res 1983;53:622-9.
36. Korthuis RJ, Kinden DA, Brimer GE, Slattery KA, Stogsdill P, Granger DN. Intestinal capillary filtration in acute and chronic portal hypertension. Am J Physiol 1988;254:G339-45.
37. Nguyen LS, Villablanca AC, Rutledge JC. Substance P increases microvascular permeability via nitric oxide-mediated convective pathways. Am J Physiol 1995;268:R1060-8.
38. Gräfe M, Bossaler C, Graf K. Auch-Schwelk W, Baumgarten CR, Hildebrandt A, et al. Effect of angiotensin-converting-enzyme inhibition on bradykinin metabolism by vascular endothelial cells. Am J Physiol 1993;264:H1493-7.
39. Tesfamariam B, Cohen RA. Inhibition of adrenergic vasoconstriction by endothelial cell shear stress. Circ Res 1988;63:720-5.
40. Rubanyi GM, Freay AD, Kauser K, Johns A, Harder DR. Mechanoreception by the endothelium: mediators and mechanisms of pressure- and flow-induced vascular responses. Blood Vessels 1990;27:246-57.
41. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide physiology, pathophysiology and pharmacology. Pharmacol Rev 1991;43: 109-42.
42. Tamaoki J, Sakai A, Kondo M, Takamura H, Konno K. Role of nitric oxide in tachykinin-induced potential difference of rabbit tracheal mucosa. J Physiol 1995;488:115-22.
43. 2 receptors in rat colonic hypersecretion induced by interleukin 1β: role of nitric oxide. Gastroenterology 1995; 109:483-9.
44. Benoit JN, Zimmerman Premen AJ, Vay Liang WG, Granger N. Role of glucagon in splanchnic hyperemia of chronic portal hypertension. Am J Physiol 1986;251:G674-7.
45. Thornton JR, Dean H, Losowsky MS. Is ascites caused by impaired hepatic inactivation of blood borne endogenous opioid peptides? Gut 1988;29:1167-72.
46. Bendtsen F, Schifter S, Henriksen JH. Increased circulating calcitonin gene-related peptide in cirrhosis. J Hepatol 1991;12: 118-23.
47. Henriksen JH, Staun-Olson P, Fahrenkrug J, Ring-Larsen H. Vasoactive intestinal polypeptide (VIP) in cirrhosis: arteriovenous extraction in different vascular beds. Scand J Gastroenterol 1980;15:787-92.
48. Lee FY, Wang SS, Tsai YT, Lin HJ, Lin HC, Chu CJ, et al. Aminoguanidine corrects hyperdynamic circulation without ameliorating portal hypertension and portal hypertensive gastropathy in portal hypertensive rats. J Hepatol 1997;26: 687-93.
49. Kenney TJ, Stefan A, Nunes DP, Offner GD, Nikulasson S, Pouthalakis C, et al. Effect of substance P and its receptor antagonist CP-96,345 on systemic arterial and portal pressure in normal and cirrhotic rats. Hepatology 1995;22:258A.